(RTTNews) - Silo Pharma, Inc. (SILO) on Tuesday announced positive early findings from its ongoing study evaluating the pharmacokinetics, safety, and tolerability of SP-26, a novel ketamine-based extended-release implant designed for chronic pain and fibromyalgia.
Key Findings from the Study:
-- No serious side effects or discomfort observed in animal testing following subcutaneous implantation.
-- Early pharmacokinetic data indicates promising absorption, distribution, metabolism, and excretion (ADME) profiles.
-- The study is progressing toward its final safety and pharmacokinetic data, with reports expected in March 2025.
-- The successful outcome could support SP-26's potential as a non-opioid treatment for chronic pain and fibromyalgia.
Silo Pharma remains optimistic about SP-26's clinical potential and plans to advance its development for FDA approval.
SILO closed Monday's (Feb.10 2025) trading at $1.54 down 5.52%. In premarket trading Tuesday, the stock is up by 1.94% at $1.56.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
